课题基金 / 基金详情

Immunomodulatory effects of cytomegalovirus-induced salivary soluble form of NHC class I

Immunomodulatory effects of cytomegalovirus-induced salivary soluble form of NHC class I
巨细胞病毒诱导的 NHC I 类唾液可溶形式的免疫调节作用
批准号:
10534609
负责人:
Taichiro Nonaka
金额:
$0.75万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-01-03 至 2022-03-31

项目摘要

项目成果

Taichiro Nonaka的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Human Cytomegalovirus (CMV) is a beta-herpesvirus that infects more than half of the US population. Although this persistent/latent infection is asymptomatic in healthy individuals, CMV causes multi-organ diseases in the immune-compromised population (e.g., AIDS patients and solid organ/hematopoietic stem cell transplant recipients). CMV causes not only oral lesions (oral ulceration, periodontal disease, sialadenitis, salivary gland tumor) but also severe systemic diseases (pneumonia, encephalitis, hepatitis, colitis, gastritis). CMV inclusions are frequent in the salivary glands of infants and adults during the course of CMV infection, and oropharyngeal shedding is now a well-established source of human-to-human transmission. We hypothesize that saliva from CMV-infected salivary gland provides immunological impact on the host. In previous reports, human natural killer (NK) cells expressing the activating CD94/NKG2C receptor (heterodimer of CD94 and NKG2C) are expressed in higher frequency in CMV-seropositive adults and preferentially respond during CMV viremia. CD94/NKG2C is known to recognize the invariant human leukocyte antigen (HLA)–E glycoprotein, which is the family of human major histocompatibility complex (MHC) class I molecules. Moreover, HLA-E is abundantly expressed in salivary gland, and soluble form of HLA ligand can be released in a metalloproteinase-dependent fashion. By these facts, we hypothesize that CMV infection alters the peptide repertoire on HLA-E ligand in salivary gland, generating high affinity ligands for the activating CD94/NKG2C receptor (or for the inhibitory CD94/NKG2A receptor), shedding soluble form of HLA-E ligands into saliva, resulting in NK cell activation (or inhibition) through mucosal immune system in oral-pharyngeal cavity (e.g., tonsil and Peyer's patch). To test this hypothesis we propose the two specific aims. Aim 1 will determine the nature of the peptides bound to HLA-E in CMV-infected versus uninfected salivary gland cells by mass spectrometric analysis. Aim 2 will identify CMV-induced HLA-E/peptide complexes that preferentially bind to the activating CD94/NKG2C versus inhibitory CD94/NKG2A receptors. In future research plan, we will assess the ability of candidate peptides to bind and activate primary human oral NK cells. Our studies are intended to determine the role of salivary soluble form of MHC class I molecule as they appear in saliva in the context of CMV infection. Further, from a clinical perspective, the studies we propose are designed to determine whether the HLA-E/peptide complexes deserve investigation as a potential new therapeutic strategy for oral CMV infection.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Immunohistochemical Profile of Polymorphous Adenocarcinoma of Minor Salivary Gland: A Systematic Review and Meta-Analysis.
小唾液腺多形性腺癌的免疫组织化学特征:系统评价和荟萃分析。
DOI: 10.1007/s12105-022-01453-6
发表时间: 2022
期刊: Head and neck pathology
影响因子: 2.1
作者: [Nonaka,Taichiro, Takei,Hidehiro]
通讯作者: Takei,Hidehiro
Defining a novel function for salivary exosomes in modulating host immunity against cancer
国内基金
海外基金
Dynamic Credit Rating with Feedback Effects
  • 批准号:
    --
  • 项目类别:
    外国学者研究基金项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    Christian Martin Hilpert
  • 依托单位:
NPM1表观重塑巨噬细胞代谢及修复表型在心肌缺血损伤中的调控作用
  • 批准号:
    82371825
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    占贞贞
  • 依托单位:
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    万杰清
  • 依托单位:
儿童期受虐经历影响成年人群幸福感:行为、神经机制与干预研究
  • 批准号:
    32371121
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2023
  • 负责人:
    孔风
  • 依托单位: